A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]
The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2020-05-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/9-373/v1 |
| _version_ | 1828838111163973632 |
|---|---|
| author | Daniele Piovani Claudia Pansieri Laurent Peyrin-Biroulet Silvio Danese Stefanos Bonovas |
| author_facet | Daniele Piovani Claudia Pansieri Laurent Peyrin-Biroulet Silvio Danese Stefanos Bonovas |
| author_sort | Daniele Piovani |
| collection | DOAJ |
| description | The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence. On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment. Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials. |
| first_indexed | 2024-12-12T18:54:25Z |
| format | Article |
| id | doaj.art-afa1f3bf95ff46969b2a8f91f8cc24e3 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-12T18:54:25Z |
| publishDate | 2020-05-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-afa1f3bf95ff46969b2a8f91f8cc24e32022-12-22T00:15:16ZengF1000 Research LtdF1000Research2046-14022020-05-01910.12688/f1000research.23843.126310A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]Daniele Piovani0Claudia Pansieri1Laurent Peyrin-Biroulet2Silvio Danese3Stefanos Bonovas4Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, ItalyNancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, FranceDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, ItalyThe pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence. On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment. Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.https://f1000research.com/articles/9-373/v1 |
| spellingShingle | Daniele Piovani Claudia Pansieri Laurent Peyrin-Biroulet Silvio Danese Stefanos Bonovas A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] F1000Research |
| title | A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] |
| title_full | A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] |
| title_fullStr | A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] |
| title_full_unstemmed | A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] |
| title_short | A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved] |
| title_sort | snapshot of the ongoing clinical research on covid 19 version 1 peer review 2 approved |
| url | https://f1000research.com/articles/9-373/v1 |
| work_keys_str_mv | AT danielepiovani asnapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT claudiapansieri asnapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT laurentpeyrinbiroulet asnapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT silviodanese asnapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT stefanosbonovas asnapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT danielepiovani snapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT claudiapansieri snapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT laurentpeyrinbiroulet snapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT silviodanese snapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved AT stefanosbonovas snapshotoftheongoingclinicalresearchoncovid19version1peerreview2approved |